Processing...
Clinical Trials for Rectal Cancer
Search
Search
There are 226 active trials for advanced/metastatic rectal cancer.
Click on a trial to see more information.
226 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with measurable, unresectable locally advanced or metastatic NSCLC adenocarcinoma, cholangiocarcinoma, colorectal cancer, or pancreatic cancer after standard therapy or without a suitable standard option receive intravenous MGC028. This investigational ADAM9-targeted antibody–drug conjugate delivers exatecan, a topoisomerase I inhibitor.
ClinicalTrials.gov ID: NCT06723236
TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors that have progressed after standard therapy or lack a standard option are eligible if at least one lesion shows uptake on [203Pb]Pb-PSV359 SPECT/CT. The imaging agent selects patients for treatment with [212Pb]Pb-PSV359, a FAP-targeted peptide that delivers alpha-particle radiation.
ClinicalTrials.gov ID: NCT06710756
TrialFetch AI summary: Patients with measurable, progressive KRAS-mutant pancreatic, colorectal, lung, platinum-resistant serous ovarian, cholangiocarcinoma, or urothelial bladder cancer after at least one standard therapy receive intravenous WEF-001 monotherapy. WEF-001 is investigational and is proposed to exploit macropinocytosis in KRAS-mutant tumors; direct KRAS inhibition has not been established.
ClinicalTrials.gov ID: NCT07148128
TrialFetch AI summary: Adults with unresectable locally advanced or metastatic solid tumors harboring specified KRAS mutations or eligible KRAS amplification receive intravenous ASP5834, an investigational agent designed to degrade mutant or amplified KRAS. Patients with KRAS-mutated colorectal adenocarcinoma may receive ASP5834 with panitumumab, an anti-EGFR antibody.
ClinicalTrials.gov ID: NCT07094204
TrialFetch AI summary: This trial enrolls previously treated patients with unresectable locally advanced, recurrent, or metastatic NSCLC, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, or left-sided colorectal cancer; prior treatment with a topoisomerase I inhibitor–payload ADC is excluded. All participants receive ALX2004, an investigational EGFR-targeting antibody–drug conjugate with a topoisomerase I inhibitor payload, at a dose determined by the study stage.
ClinicalTrials.gov ID: NCT07085091
TrialFetch AI summary: Adults with measurable, locally advanced or metastatic KRAS-mutant or KRAS-amplified solid tumors who have no remaining standard treatment options or have declined them receive oral AMG 410, a reversible pan-KRAS inhibitor, alone or with the PD-1 inhibitor pembrolizumab. Patients with colorectal or pancreatic cancer may receive AMG 410 with the EGFR-targeting antibody panitumumab.
ClinicalTrials.gov ID: NCT07094113
TrialFetch AI summary: Adults with measurable metastatic melanoma, colorectal cancer, pancreatic ductal adenocarcinoma, or head and neck squamous cell carcinoma harboring selected MAPK-pathway mutations, ECOG 0–1, and no suitable standard therapy receive oral IPN01194 monotherapy. IPN01194 inhibits ERK1/2, downstream components of MAPK signaling.
ClinicalTrials.gov ID: NCT06305247
TrialFetch AI summary: Adults with measurable, unresectable locally advanced or metastatic solid tumors after standard therapy or without a suitable standard option receive oral CT3001 monotherapy, an investigational GPR35 inhibitor intended to suppress YAP signaling. Dose expansion is limited to patients with advanced colorectal cancer or pancreatic ductal adenocarcinoma.
ClinicalTrials.gov ID: NCT06598007
TrialFetch AI summary: Adults with unresectable advanced or metastatic MSI-H/dMMR solid tumors, generally after progression on anti-PD-(L)1 therapy, receive oral MOMA-341 alone or with irinotecan or an unspecified immunotherapy. MOMA-341 is an investigational covalent inhibitor of WRN helicase, which MSI-H/dMMR tumors depend on for DNA maintenance.
ClinicalTrials.gov ID: NCT06974110
TrialFetch AI summary: Adults with unresectable locally advanced or metastatic NSCLC, colorectal cancer, or head and neck squamous cell carcinoma and ECOG performance status 0–1 receive JNJ-95437446, an investigational EGFR/MET-targeting antibody–drug conjugate that delivers an exatecan-derived topoisomerase I inhibitor. The study evaluates dose and safety; no human safety or efficacy results have been reported.
ClinicalTrials.gov ID: NCT07107230